@ShahidNShah
The adaptive nature of artificial intelligence (AI), with its ability to improve performance through continuous learning, offers substantial benefits across various sectors. However, current regulatory frameworks are not intended to accommodate this adaptive nature, and they have prolonged approval timelines, sometimes exceeding one year for some AI-enabled devices. This creates significant challenges for manufacturers who must deal with lengthy waits and submit multiple approval requests for AI-enabled device software functions as they are updated. In response, regulatory agencies like the US Food and Drug Administration (FDA) have introduced guidelines to better support the approval process for continuously evolving AI technologies.
AI regulation in healthcare is evolving to keep pace with continuously learning systems, and the study highlights how the U.S. FDA’s Predetermined Change Control Plans (PCCPs) can streamline approvals while maintaining safety and compliance.
Continue reading at ai.jmir.org
Large language models are rapidly transitioning from pilot schemes to routine clinical practice. This creates an urgent need for clinicians to develop the necessary skills to strike the right balance …
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2026 Netspective Foundation, Inc. All Rights Reserved.
Built on Mar 26, 2026 at 3:36pm